Organigram Global Inc. (OGI)
(Delayed Data from NSDQ)
$1.33 USD
-0.01 (-0.75%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $1.34 +0.01 (0.75%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OGI 1.33 -0.01(-0.75%)
Will OGI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OGI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OGI
Beat the Market the Zacks Way: Curtiss-Wright, Oracle, Starbucks in Focus
OrganiGram (OGI) Reports Q2 Loss, Beats Revenue Estimates (Revised)
OGI: What are Zacks experts saying now?
Zacks Private Portfolio Services
OrganiGram (OGI) Reports Q2 Loss, Misses Revenue Estimates
InfuSystems Holdings, Inc. (INFU) Reports Q1 Loss, Tops Revenue Estimates
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates
Other News for OGI
Organigram to Report Third Quarter Fiscal 2025 Results on August 13, 2025 | OGI Stock News
Tilray sends pot stocks lower after Q4 results
Village Farms: Why It Is Time To Move To The Sidelines
U.S. Senate confirms President Trump’s DEA pick
Marijuana rescheduling process remains stalled, DEA says